AbCellera ($ABCL): Q3 Results on November 9 and the Next Clinical Tests

01 Post-readout scenarios

Constructive scenario

The 12-week ABCL635 follow-up preserves clinically meaningful efficacy and clean liver safety, and regulators accept a practical late-stage path. The priced offering’s 5.9% discount and 6.7% dilution prove not to weigh on the multiple. ABCL575 delivers useful Phase 1 pharmacology in Q4, while partner receipts and public funding offset part of the internal-pipeline burn.

Base scenario

The week-4 effect is real but fades partially by week 12 or requires additional dose work. AbCellera raises the full capital, launches another study and remains well funded, but the larger share base and uncertain registrational path limit per-share re-rating until more data arrive.

Adverse scenario

Longer follow-up weakens efficacy, reveals safety or makes monthly dosing less compelling. A further financing, if needed before Phase 3 readouts, prices at a steeper discount than the August round and adds a large warrant component, creating greater dilution before the asset is ready for Phase 3. Fixed infrastructure and clinical spending then consume a larger capital base without comparable de-risking.

Checks that could change this assessment

This page assesses AbCellera through its four-week internal clinical result, partnered portfolio and dated financial resources. The following checks could strengthen or weaken that assessment; each requires a presentation, filing or partner disclosure.

• Longer follow-up changes the four-week interpretation. What has been published is a four-week result from a single 600 mg subcutaneous dose in 92 participants: an 83% reduction in vasomotor symptoms against 33% on placebo, 5.3 fewer moderate-to-severe hot flashes a day. Safety detail, missing-data handling and longer follow-up are the evidence needed to interpret durability; an announced conference slot alone does not establish those findings. No exact twelve-week readout date is established by the cited conference invitation.
• Durability or repeat-dose safety fails. A single dose measured at four weeks does not establish what happens on chronic dosing, which is how a menopause treatment would actually be used. Repeated-dose evidence is one of several requirements for assessing a potential chronic treatment.
• ABCL575 results and timing. The company guided Phase 1 topline to Q4 2026. Results could strengthen or weaken confidence in a second internal program. A delay would require explanation and could increase reliance on ABCL635 for near-term internal-pipeline evidence, while other internal assets and the partnered portfolio retain separate opportunities and risks.
• The partnered portfolio stops advancing. AbCellera holds downstream economic interests in 35 partner programmes. Those royalties and milestones are the part of the business that does not depend on its own trials, and a partner discontinuing a programme removes value without any announcement from AbCellera itself.
• The cash stops being enough. Cash and securities were $540.1 million at June 30, 2026, with company-stated available liquidity above $675 million at August 5 including roughly $110 million of public funding. Both observations precede the $200 million offering priced on August 12; confirmation of closing and receipt of its proceeds is a separate matter. Q2 net loss of $55.4 million is not cash burn. H1 operating cash use was $7.6 million, affected by partner advances; future clinical spending can increase cash use.

These are monitoring questions, not predictions or automatic valuation rules. Assess the content, timing and materiality of new evidence before changing the conclusions.

02 The ABCL635 Phase 2 Result, Line By Line

AbCellera released week-4 top-line data before the open on August 10, 2026 and filed the full presentation as exhibit 99.2 to a Form 8-K the same morning. The trial (NCT07118891) is a multicentre, randomised, double-blind, placebo-controlled study in postmenopausal women aged 40 to 75. It planned about 80 patients and randomised 92, 46 to a single 600 mg subcutaneous dose of ABCL635 and 46 to placebo, with an optional open-label extension. The data cut-off is July 30, 2026. Baseline characteristics were balanced: mean age 58.7 against 59.7, mean body mass index 27.1 against 27.4, and a mean of 10.6 against 9.8 moderate-to-severe hot flashes a day.

On frequency, one of the two primary efficacy endpoints the company reports as met, ABCL635 reduced moderate-to-severe hot flashes by a mean of 83% from baseline at week 4 against 33% on placebo, a placebo-adjusted difference of 50 percentage points. In absolute terms the placebo-adjusted treatment difference was 5.3 fewer episodes a day at week 4 and 2.6 as early as week 1. On severity the reduction was 58% against 12%, a placebo-adjusted difference of 46 points, with the mean severity score at week 4 falling to 1.0, which the scale calls mild, against 2.1 on placebo, which it calls moderate. The company states that the effect was consistent across subgroup and sensitivity analyses.

The response-threshold table is the part that is hard to explain away. Complete resolution of moderate-to-severe hot flashes at week 4 was reached by 37.0% of the ABCL635 arm against 2.2% of placebo. More than 90% reduction was reached by 60.9% against 8.7%, more than 75% by 78.3% against 15.2%, and more than 50% by 87.0% against 32.6%. On severity, complete resolution was 26.1% against 2.2%. The randomized between-group differences support a treatment effect over four weeks; response thresholds do not independently establish durability or superiority to approved treatments.

The quality-of-life measures moved with the symptom scores. On the PROMIS sleep disturbance short form the treatment difference was 5.5 points at week 4, with improvement across all eight components including trouble falling asleep, staying asleep and sleep quality. On the patient global impression of change, 84% of ABCL635 patients rated their symptoms as much better or moderately better against 27% on placebo, with significant differences from week 1.

Safety: the point of the whole exercise

There were no serious adverse events and no grade 3 or higher adverse events in the ABCL635 arm. The placebo arm had one serious adverse event and two grade 3 events. Any adverse event was reported in 67.4% of ABCL635 patients against 52.2% on placebo, with headache the most common at 28.2% against 13.0%, fatigue at 13.0% against 6.5% and injection site reactions at 8.7% against 6.5%. No gastrointestinal safety signal was identified in this small four-week dataset. One ABCL635 patient had a mild rise in transaminases, AST 92 and ALT 66 international units per litre, which resolved within a week; one placebo patient reached ALT of 121. Mean liver function tests remained stable across the arm.

What the company said it will do next

Management plans twelve-week follow-up for dose selection and regulatory discussions on late-stage development in menopausal and oncology-treatment VMS. The October 1 conference is historical; its available materials document the four-week result. No exact date for later follow-up is established here.

On market size the company estimates approximately 12 million women in the United States with moderate-to-severe vasomotor symptoms, more than 6 million of whom seek treatment, and about 20% for whom hormone therapy is unsuitable, giving more than 1 million who could benefit from a safe non-hormonal option. It puts the total addressable market above $6 billion assuming net-price parity of roughly $5,000 per patient per year with the approved small molecules. Those are management estimates built on census data and published literature, stated as such in the presentation, not independent market research.

03 What changed in 2026

04 What AbCellera is

AbCellera is a Vancouver-based clinical-stage biotechnology company focused on antibody-based medicines. Its integrated capabilities span target identification, antibody discovery, screening, protein engineering, translational work, process development, and early clinical manufacturing. Historically, the company applied these tools mainly to partner programs. It now uses the same infrastructure to advance internal programs in endocrinology, women’s health, immunology, autoimmunity, and oncology.

This evolution is important because the company is seeking to capture more of the economics created by its platform. In a traditional discovery partnership, AbCellera may receive research fees and retain rights to milestones or royalties, but the partner generally controls development priorities, timing, disclosure, and commercialization. In an internally led program, AbCellera controls the asset and can retain a larger share of future value, partner it later, or develop it further on its own.

The trade-off is obvious. Greater ownership requires greater spending. Research and development expense reached $186.8 million in 2025 and remained elevated at $46.7 million in Q1 2026. This is not a low-cost licensing model anymore. It is a clinical-development organization with expensive infrastructure and a portfolio that will require disciplined prioritization.

How to classify the stock

The most useful classification is a cash-rich clinical-stage biotech with a partner-supported discovery engine. The platform and partner portfolio provide diversification and potential non-dilutive inflows, but near-term stock sensitivity is increasingly tied to internally controlled clinical assets—especially ABCL635.

05 The antibody platform: strengths, economic logic and limitations

AbCellera’s platform was built to solve difficult antibody-discovery problems, including challenging membrane proteins, GPCRs, ion channels, multispecific antibodies, and other target classes that can be difficult to address using conventional workflows. The core proposition is not merely that the company can find antibodies; it is that its integrated system can identify, characterize, engineer, and manufacture differentiated candidates with fewer handoffs and better control over decision quality.

Partner metrics require careful reading

AbCellera changed its reported business metrics in Q1 2026 to focus on programs that it believes are progressing and in which it retains downstream economics. At March 31, partners led 40 such programs, down from 44 at year-end, and AbCellera reported downstream stakes in 14 clinical molecules believed to be progressing.

The decline from 44 to 40 is not automatically a negative signal of platform deterioration. Partner portfolios are routinely reprioritized, and AbCellera has limited visibility into many external programs. It does, however, illustrate why the historical cumulative-program count could overstate the active economic opportunity. The revised metrics are more conservative and more useful, even though outside investors still lack asset-level detail for much of the portfolio.

The main platform limitation

Partner optionality is broad but hard to value. Most programs may never reach approval, the timing of milestone recognition is uneven, royalty rates vary, and the company cannot force partners to advance a molecule. The partner portfolio should therefore be treated as a potentially valuable long-tail asset—not as a predictable revenue stream that offsets internal R&D on a quarterly basis.

06 Updated pipeline overview

The pipeline is more credible after ABCL635, but evidence remains concentrated. Only one internal program has demonstrated clinical benefit, and only at week 4. ABCL575 is primarily a technical and partnering event; ABCL688 and ABCL386 remain preclinical.

07 ABCL635: what Phase 2 proved and what remains open

ABCL635 is a fully human antibody against NK3R, a clinically validated pathway in vasomotor symptoms. The proposed differentiation is monthly subcutaneous dosing with durable control and without the liver-monitoring burden associated with some oral therapy.

Separation was visible from week 1, when ABCL635 produced 2.6 fewer daily moderate-to-severe events versus placebo. At week 4 the result is compelling, but competitive value depends on persistence through week 12, complete injection-site and immunogenicity data, the selected dose and the design the FDA will require.

The company’s comparisons with fezolinetant and elinzanetant are cross-study, not head-to-head. Population, baseline burden, placebo response, endpoint and analysis differences prevent a superiority claim. “Potential best-in-class” is a development thesis, not a conclusion established by this topline.

The next disclosure point is dated. AbCellera announced on October 8, 2026 that poster P-92 at The Menopause Society 2026 Annual Meeting, on October 22, 6:15–7:15 p.m. PDT, will add new safety data from the Phase 1 multiple-ascending-dose study and new patient-reported outcome data from the Phase 2 study. Patient-reported outcomes can help judge whether the reduction in hot flashes is meaningful to patients, but the poster has not yet been published, so no conclusion can be drawn in advance. Company release

Late-stage checklist

• Persistence of efficacy through week 12 and across monthly dosing.
• Confidence intervals, missing-data handling, subgroup consistency and patient-level distribution.
• Injection-site reactions, immunogenicity, liver enzymes, discontinuations and serious events.
• Final dose, number and duration of registrational trials, comparator and geography.
• Strategy across menopausal and oncology-treatment VMS.
• Manufacturing, cost, reimbursement and any partnership strategy.

08 ABCL575: scientifically interesting, strategically less central

ABCL575 is an Fc-silenced, half-life-extended antibody targeting OX40 ligand, or OX40L. It is being studied initially in healthy volunteers as a potential treatment for atopic dermatitis and possibly other inflammatory or autoimmune diseases. The Phase 1 study, NCT07108894, is randomized, double-blind, placebo-controlled, and designed to evaluate single ascending subcutaneous doses across five planned cohorts of eight participants each.

The asset was engineered around a very long dosing interval. AbCellera has discussed a potential once-every-six-months profile, which would be highly differentiated if clinical activity, durability, and safety support it. That ambition is important because atopic dermatitis is already served by effective biologics and oral agents, and the development landscape includes several late-stage programs directed at OX40 or OX40L.

Amlitelimab: historical results and the subsequent AD discontinuation

Sanofi discontinued amlitelimab development in atopic dermatitis on July 24, 2026, and said it would not make global AD submissions because the total efficacy and safety package did not support further development. The separate Phase 2 celiac program remained ongoing in that announcement. This supersedes the earlier March Phase 3 development narrative; it neither proves nor invalidates ABCL575. Sanofi July 24 decision.

The strategic caveat that investors should not miss

AbCellera stated in its Q1 2026 Form 10-Q that it currently has no plan to pursue ABCL575 development beyond Phase 1. That does not mean the asset lacks value. It may be intended for partnering, licensing, or a decision after data. It does mean that a fully funded AbCellera-led Phase 2 and Phase 3 program is not the base case unless management changes that position.

The Q4 2026 topline readout is primarily a technical and partnering event: safety, tolerability, exposure, half-life, and target-relevant pharmacology will determine whether ABCL575 becomes an attractive external-development opportunity. It is not currently the main internal-commercialization asset.

09 ABCL688, ABCL386 and the next wave

ABCL688 and ABCL386 test whether the internal engine can produce additional viable clinical candidates.

ABCL688 is described as an autoimmunity program aimed at a difficult membrane-protein target within the areas where AbCellera believes its GPCR and ion-channel capabilities can create an edge. ABCL386 is an undisclosed oncology antibody. Both are in IND- or CTA-enabling work. The Q2 guidance targets an IND or CTA for ABCL688 in 2027 and initiation of a Phase 1/2 trial in patients for ABCL386 in 2027; these are distinct milestones.

Disclosure remains too limited to underwrite either candidate independently. Investors do not yet have enough public information about target biology, preclinical efficacy, differentiation, toxicology, manufacturing, or the intended clinical path. Their present value lies in pipeline breadth and platform validation. Their future value will depend on target disclosure, development timelines, and the quality of preclinical packages.

Management also expects to select at least one additional development candidate during 2026. That milestone is strategically important but is not clinical de-risking. Candidate selection creates a new option; it does not establish product value.

10 The Jazz Pharmaceuticals agreement: better than a routine discovery deal

The June 2026 Jazz collaboration is one of the most important platform validations since AbCellera began emphasizing its proprietary pipeline. The companies will work on next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

Why the deal is strategically important

First, it provides immediate cash without issuing shares. Second, Jazz committed substantial upfront capital to preclinical work, which suggests the partner sees value in the platform rather than treating AbCellera as a commodity service provider. Third, the deal can use multiple parts of AbCellera’s integrated stack, including multispecific design, early development, and manufacturing.

The agreement also helps balance the internal-pipeline pivot. AbCellera can retain high ownership in selected proprietary programs while continuing to monetize the platform through partners. That hybrid model is potentially attractive because partner capital can reduce net burn and validate new capabilities.

Accounting caution

The $56 million upfront payment should not automatically be treated as $56 million of immediate Q2 revenue. Revenue recognition may depend on performance obligations and the timing of research activities. The Form 10-Q filed on August 5, 2026 sets out the cash, receivable, deferred-revenue and recognised-revenue treatment, and the Q2 financial chapter below works through it. The economic value is real; the quarterly income-statement presentation may be spread over time.

11 Q2 financial position, burn and runway

Including restricted cash, balance-sheet liquidity was approximately US$567.1 million. The company reported more than US$675 million of available liquidity after including roughly US$110 million of non-dilutive government funding. These categories are not interchangeable: public funding can carry restrictions and restricted cash is not fully deployable.

First-half operating cash use was only US$7.6 million because partner upfronts increased deferred revenue. That is not a normalized structural burn rate: operating loss and R&D show a much higher economic cost. A US$200 million offering can extend runway and fund ABCL635, but future burn depends on Phase 3 size and the number of programs run in parallel.

First-half 2026 operating cash use of $7.6 million divided by six is about $1.27 million per month. It is a historical net measure affected by partner advances, including an increase in deferred revenue; it is not a normalized development burn or a forecast. The June 30 cash and securities balance was $540.104 million excluding restricted cash. Government funding and the August financing have separate conditions and dates. Q2 company statements.

12 Capital structure, the August offering and dilution risk

AbCellera reported 306,611,466 common shares outstanding at August 3, 2026. Equity compensation and option exercises had already increased the share count before the August financing.

August 2026 offering: priced; closing was expected on August 14

AbCellera commenced an underwritten public offering of common shares and, for certain investors, pre-funded warrants on August 11, 2026. The offering priced on August 12 at US$9.75 per share with delivery expected on or about August 14, subject to conditions. All securities were primary. The stated intended use of proceeds is the internal pipeline, including ABCL635, as well as working capital and general corporate purposes; this does not verify actual collection or deployment. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets were joint bookrunners.

Pre-funded warrants are economically close to common stock because almost the entire purchase price was paid upfront and the residual exercise price is nominal. They may delay the formal reported common-share count until exercised, but they are included in the economic-dilution figure above.

The financing was not an emergency rescue: AbCellera had US$540.1 million of cash and securities at June 30 and more than US$675 million of company-defined available liquidity. It was an opportunistic post-data raise intended to fund a more expensive late-stage path. That can be strategically sensible and still materially dilute existing owners.

Equity compensation remains a second channel

Q2 stock-based compensation and outstanding employee options transfer economic value over time independently of the offering. A complete per-share analysis therefore needs the final offering security count, pre-funded warrants, options, restricted units and future awards.

13 Insider and major-holder alignment

The 2026 proxy provides unusually strong evidence of founder and insider ownership. Beneficial ownership calculations include shares that could be acquired through options within 60 days, so they are not identical to simple current common-share holdings. They are nevertheless useful for understanding control and alignment.

Open-market director purchases after the offering

Two directors bought common shares on the open market in the days after the August 12 pricing, both reported on Form 4 as code P purchases rather than option exercises or awards. John S. Montalbano acquired 10,000 shares at 11.03 dollars on August 18, taking his direct holding to 251,000 shares. Michael R. Hayden acquired 53,613 shares at 10.64 dollars on August 24, taking his indirect holding through Genworks 2 to 1,373,397 shares, alongside 118,245 shares held indirectly.

Both purchases were made above the 9.75 dollar price at which the August offering was placed. Two directors buying roughly 0.7 million dollars of stock between them is a small transaction against a company of this size, and it says nothing about the week-12 dataset; what it does show is that the people who saw the offering priced chose to add to their own positions afterwards rather than sell into the move. Source: Forms 4 filed with the SEC on August 18 and August 24, 2026.

High insider ownership is generally positive for alignment, but it also concentrates influence. Founder control can support long-term investment that public markets might otherwise resist, yet it may reduce outside shareholders’ practical influence over strategy, compensation, and capital allocation. Investors should evaluate outcomes rather than assuming that ownership alone guarantees efficient decisions.

14 Management, board and execution

Carl Hansen remains chairman, president and CEO; Véronique Lecault is chief technology officer, Andrew Booth is chief financial officer and Sarah Noonberg is chief medical officer. The leadership task has moved from generating the first efficacy signal to selecting dose and registrational design, financing prudently and prioritizing a broad portfolio.

Updated 2026 execution scorecard

• Verify closing and deployment of the priced August financing against the late-stage plan, with attention to per-share economics.
• Deliver the ABCL635 week-12 follow-up and complete safety dataset.
• Reach regulatory alignment on dose and late-stage design.
• Complete ABCL575 Phase 1 and define a partner or development strategy.
• Monitor the distinct 2027 targets: an IND or CTA for ABCL688, and Phase 1/2 patient-trial initiation for ABCL386.
• Integrate Jazz and Vertex work while maintaining spending discipline.
• Show that manufacturing investment improves speed and economics rather than only fixed cost.

15 Valuation framework after efficacy and after offering pricing

This is not an earnings-multiple story. A useful valuation separates unrestricted cash and securities; restricted cash and public funding; probability-adjusted ABCL635 value; partner-program economics; other internal pipeline options; and the future corporate cost required to develop them.

ABCL635 deserves more probability weight after demonstrating placebo-adjusted patient benefit. The public evidence still does not support a precise rNPV: week-12 durability, final dose, registrational design, trial count, timing, pricing, uptake and future costs remain unknown.

The August prospectus fixes the proposed financing security counts: 17,435,897 common shares at $9.75 and pre-funded warrants for a further 3,076,926, priced on August 12, 2026. A complete picture includes common shares, pre-funded warrants, employee equity, net proceeds and the incremental burn required by the late-stage plan.

What appears priced in

The US$9.32 August 10 reference sale in the preliminary prospectus implies a materially higher equity value than the July pre-readout snapshot. That is consistent with the market assigning value to the positive data, but it is not a stable post-offering valuation and cannot be multiplied by a hypothetical share count.

No formal target price

Merlintrader does not assign a target. A defensible range incorporates the priced terms, separately verified closing, and enough week-12 and regulatory detail to model probability, timing, cost and dilution rather than extrapolating a four-week headline.

16 Principal risks and red flags

Durability and dose

The reported efficacy covers four weeks after a single dose. A monthly product must retain sufficient control through the full interval and across repeated dosing; week-12 follow-up can change the program’s interpretation.

Safety at scale

Ninety-two Phase 2 participants cannot define uncommon liver, immune, injection-site or neuroendocrine events. Larger and longer studies can reveal issues absent from the topline.

Competitive standard

ABCL635 enters a market with approved oral NK-pathway drugs and hormone therapy. Monthly injection is a benefit only if efficacy, safety, price and access make it worthwhile.

Dilution

The August 2026 offering is priced and its allocation is public: 6.7 per cent on the June 30, 2026 share count, at a 5.9 per cent discount to the August 12 close. Pre-funded warrants are economically close to shares and belong in any per-share calculation. Actual closing, subsequent cash use and future financing remain separate questions: the late-stage ABCL635 programme has no design, no trial count and no budget yet, and equity is the stated funding mechanism.

Fixed-cost and portfolio risk

Clinical infrastructure, manufacturing and a broad pipeline consume cash. More capital can reduce financing risk while increasing the risk of funding too many programs without sufficient prioritization.

Partner opacity

AbCellera has limited control over partner-led assets. Attrition, reprioritization and delayed disclosure make future milestones and royalties difficult to forecast.

17 Monitoring checklist for investors

• Offering proceeds: verify actual closing and how any collected August proceeds are deployed against the late-stage plan, and the fully diluted count once the pre-funded warrants are exercised.
• ABCL635 efficacy: week-12 frequency and severity, confidence intervals, subgroup consistency, sleep and PGI-C.
• ABCL635 safety: liver enzymes, serious events, discontinuations, injection-site reactions and immunogenicity.
• Regulatory path: end-of-Phase-2 interaction, dose, number and size of trials, comparator, timing and geographies.
• Competitive profile: persistence, convenience, monitoring, price and access versus approved oral agents.
• Cash: unrestricted balance, operating cash use, capex, public reimbursements and post-offering pro forma.
• IMS materials acquired October 2, 2026: review population, analysis, safety and the four-week result. The scheduled October 1 oral slot is historical. The file does not establish twelve-week durability; subsequent follow-up needs its own evidence.
• ABCL575: Q4 half-life, pharmacology, tolerability and partnering plan.
• Pipeline: ABCL688/386 regulatory timing, additional candidate selection and partner-program attrition.
• Per-share discipline: diluted shares, warrants, options, stock compensation and spending per milestone.
• AbCellera — presentation of Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting, October 8, 2026 (Business Wire)

Finviz data as of October 2, 2026 at 17:47:35 UTC / 19:47:35 CEST: intraday market capitalization $4.47B, Finviz shares 306.47M, float 253.59M, short float 13.38% (33.93M shares short), short ratio 4.97, institutional ownership 36.62% and insider ownership 21.74%. The prior regular-session close was $13.91 on October 1; the capitalization is intraday, not that closing capitalization. The data date and the short-interest settlement date differ; the third-party share count is not a substitute for the dated SEC count. Finviz.

The prior historical retail-percentage series has no archived record sufficient to verify its values. Social messages express opinions and attention, rather than clinical efficacy or commercial demand.